Smart Global Holdings (SGH) Buy Rating Reiterated by Needham; With $20.0000 Target; Integra Lifesciences Holdings (IART) Covered By 8 Bulls

June 19, 2017 - By Hazel Jackson

Among 10 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Integra Lifesciences Holdings Corp. had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, July 29 by Raymond James. As per Thursday, November 12, the company rating was initiated by Citigroup. The firm has “Equal Weight” rating by Barclays Capital given on Friday, July 29. The firm has “Buy” rating given on Monday, December 12 by UBS. The rating was maintained by Lake Street on Wednesday, August 26 with “Hold”. The firm earned “Buy” rating on Tuesday, May 30 by Jefferies. The firm has “Mkt Outperform” rating given on Friday, January 6 by JMP Securities. Lake Street maintained Integra Lifesciences Holdings Corp (NASDAQ:IART) rating on Thursday, April 28. Lake Street has “Hold” rating and $75 target. The company was upgraded on Friday, October 28 by Lake Street. The company was upgraded on Monday, September 21 by Bank of America. See Integra Lifesciences Holdings Corp (NASDAQ:IART) latest ratings:

30/05/2017 Broker: Jefferies Rating: Buy New Target: $58.0000 Maintain
13/01/2017 Broker: RBC Capital Markets Rating: Sector Perform Old Target: $85 New Target: $46 Maintain
06/01/2017 Broker: JMP Securities Old Rating: Mkt Perform New Rating: Mkt Outperform Upgrade

Needham have a $20.0000 target price per share on the stock. The target price per share gives a potential upside of 11,664.71% from Smart Global Holdings Inc (SGH)‘s last price. This rating was released in an analyst note on 19 June.

Integra LifeSciences Holdings Corporation is a medical technology company. The company has market cap of $4.00 billion. The Firm focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. It has a 62.57 P/E ratio. The Company’s divisions include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Investors sentiment decreased to 1.13 in 2016 Q4. Its down 0.21, from 1.34 in 2016Q3. It is negative, as 37 investors sold Integra Lifesciences Holdings Corp shares while 58 reduced holdings. 29 funds opened positions while 78 raised stakes. 33.92 million shares or 4.02% more from 32.61 million shares in 2016Q3 were reported. Federated Investors Pa holds 0% or 17,030 shares in its portfolio. Loomis Sayles Co Ltd Partnership reported 167,428 shares stake. Cambridge Co accumulated 9,467 shares or 0.06% of the stock. 49,800 are owned by Gam Ag. Foundry Ptnrs Limited Liability Company invested 0.08% of its portfolio in Integra Lifesciences Holdings Corp (NASDAQ:IART). State Common Retirement Fund reported 65,183 shares stake. Westfield Capital Mngmt Comm Ltd Partnership owns 348,146 shares for 0.26% of their portfolio. 8,688 were accumulated by Advsr Asset. Mason Street Advisors Ltd Limited Liability Company reported 0.02% stake. Moreover, Dimensional Fund Advsrs Lp has 0.04% invested in Integra Lifesciences Holdings Corp (NASDAQ:IART) for 854,599 shares. Vanguard Group accumulated 0.01% or 2.61M shares. Hanseatic Mngmt owns 13,725 shares for 0.66% of their portfolio. Voya Inv Mgmt Limited Liability Company invested 0% of its portfolio in Integra Lifesciences Holdings Corp (NASDAQ:IART). Next Financial invested in 125 shares. Metropolitan Life Ins Ny invested in 0.01% or 20,896 shares.

The stock increased 0.13% or $0.07 on June 16, reaching $52.79. About shares traded. Integra Lifesciences Holdings Corp (NASDAQ:IART) has risen 32.67% since June 19, 2016 and is uptrending. It has outperformed by 15.97% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Hazel Jackson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Google Plus